<DOC>
	<DOCNO>NCT00171886</DOCNO>
	<brief_summary>Primary Acromegaly clinical metabolic disease cause growth hormone ( GH ) hypersecretion pituitary adenoma insidious , chronic disease associate bony soft tissue overgrowth . Goals therapy eradicate tumor , suppress GH secretion , normalize IGF-I level , preserve normal pituitary function . This study evaluate safety efficacy octreotide primary therapy treatment acromegaly therapy patient acromegaly pituitary macroadenoma microadenoma .</brief_summary>
	<brief_title>Octreotide Efficacy Safety First-line Acromegalic Patients</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Males females 18 &lt; 80 year old . Recently diagnose previously treat patient acromegaly . Presence pituitary tumor ( microadenoma macroadenoma ) , document MNR perform 12 week enrolment . Absence nadir suppression nadir GH &lt; 1.0 ng/mL , oral administration 75 g glucose ( OTTG ) . IGFI level normal upper limit , e.g . 97 percentile ( age sexmatched ) . Tolerance show test subcutaneous injection octreotide Written Informed Consent procedure specific study . Inclus Previously treat patient therapy acromegaly , include surgery , radiotherapy , bromocriptin , somatostatin analogue . Compression optic chiasm produce impairment field vision . Need surgery improve neurological sign symptom associate direct incidence tumour . Intolerance octreotide component Sandostatin® LAR® preparation . Patients hepatic condition cirrhosis , active persisting chronic hepatitis , hepatopathy fast evolution . Pregnant woman History alcohol drug abuse six month prior inclusion visit . Patients suffer condition may jeopardize interpretation study result may impede obtain informed consent Intake investigational drug study 30 day patient inclusion study Other protocoldefined inclusion / exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Acromegaly</keyword>
	<keyword>Otreotide</keyword>
	<keyword>Tumor reduction</keyword>
</DOC>